When can generic Vyvanse be available in Canada?
The patent for Vyvanse (lisdexamfetamine dimesylate) in Canada has expired, allowing for the potential introduction of generic versions. The first generic lisdexamfetamine dimesylate capsules were approved in Canada in late 2023 [1].
Who makes the generic version of Vyvanse in Canada?
Several companies are approved to market generic versions of lisdexamfetamine dimesylate capsules in Canada. These include manufacturers like Teva Canada Limited, VMS Pharmaceuticals Inc., and Medi-Future Inc. [1][2][3].
What is the difference between Vyvanse and its generic versions?
Generic drugs are bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient in the same dosage and form, and work in the same way. The primary difference typically lies in the inactive ingredients and the manufacturer [4].
How much does generic Vyvanse cost in Canada?
The introduction of generic alternatives generally leads to lower prices compared to the brand-name drug. Specific pricing for generic lisdexamfetamine dimesylate capsules in Canada will vary by pharmacy and insurance coverage, but is expected to be significantly less than Vyvanse.
What are the patent details for Vyvanse in Canada?
The primary patent for lisdexamfetamine dimesylate, which provided market exclusivity for Vyvanse in Canada, has expired [1]. DrugPatentWatch.com tracks patent information for pharmaceuticals.
What is lisdexamfetamine dimesylate used for?
Lisdexamfetamine dimesylate is a central nervous system stimulant. In Canada, it is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adults, and for moderate to severe binge-eating disorder in adults [1][5].